FinancialBuzz.com’s latest
Affimed N.V.
(NASDAQ: AFMD) surged over 30% in premarket trading after the company announced positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center.
The study evaluated cord blood-derived natural killer cells pre-complexed with Affimed’s innate cell engager and all four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK p
Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cells
Share Article
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or resistance to immune checkpoint inhibitors, drugs that help the body’s immune system recognize and attack cancerous cells. NEW YORK (PRWEB) April 09, 2021 Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatu
Olaris, Inc. Announces Presentation on Metabolic Biomarkers of Response in Advanced GIST at American Association for Cancer Research (AACR) 2021 Annual Meeting
Share Article
Olaris to present new data on metabolic signatures predictive of overall survival and therapeutic response in advanced GIST at upcoming AACR Virtual Meeting
This study is particularly exciting as we were able to demonstrate and validate in an independent set of patient samples that metabolite biomarkers either before treatment or during treatment can identify patients with favorable clinical outcomes.” - Dr. Elizabeth O’Day, CEO and Founder of Olaris WALTHAM, Mass. (PRWEB) April 09, 2021 Olaris, Inc, a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, is pleased to announce the company’s presentation on
Genes and immune cells predict immunotherapy success in bladder cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord .
Affimed N.V.April 9, 2021 GMT
All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%
There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease
Study is continuing enrollment of the second dose cohort
Company to host conference call/webcast on April 14 at 4:05 p.m. EDT
ADVERTISEMENT
Heidelberg, Germany, April 9, 2021
– Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evalu